A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‑1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.
Maha Hussain
Consultant or Advisory Role - ImClone Systems
Dana E. Rathkopf
No relevant relationships to disclose
Glenn Liu
Research Funding - ImClone Systems
Andrew J. Armstrong
Consultant or Advisory Role - Active Biotech; Amgen; Bristol-Myers Squibb; Dendreon; Medivation (U); Sanofi
Honoraria - Amgen; Dendreon; Johnson & Johnson; Pfizer; Sanofi
Research Funding - Active Biotech; Bristol-Myers Squibb; Dendreon; ImClone Systems; Medivation; Novartis; Pfizer; Sanofi
William Kevin Kelly
Consultant or Advisory Role - ImClone Systems
Anna C. Ferrari
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
Ling Yang
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Jonathan D. Schwartz
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Celestia S. Higano
Consultant or Advisory Role - ImClone Systems
Honoraria - ImClone Systems
Research Funding - ImClone Systems
Other Remuneration - ImClone Systems